A Real-World Comparison Between Adjuvant Docetaxel with Cyclophosphamide (TC) and Anthracycline–Taxane Chemotherapy in Early HER-2 Negative Breast Cancer

A Real-World Comparison Between Adjuvant Docetaxel with Cyclophosphamide (TC) and Anthracycline–Taxane Chemotherapy in Early HER-2 Negative Breast Cancer

Background: Anthracycline–taxane chemotherapy is the gold standard in high-risk breast cancer (BC), despite the potential risk of congestive heart failure (CHF). A suitable alternative for anthracycline-sparing chemotherapy is through the combination of docetaxel and cyclophosphamide (TC). Methods:...

Full description

Saved in:
Bibliographic Details
Main Authors: Danilo Giffoni de Mello Morais Mata, Rossanna C. Pezo, Kelvin K. W. Chan, Ines Menjak, Andrea Eisen, Maureen Trudeau
Format: Article
Language:English
Published: MDPI AG 2024-12-01
Series:Current Oncology
Subjects:
human epidermal growth factor receptor 2 negative
endocrine (hormone) receptor
paclitaxel
doxorubicin
epirubicin
adjuvant
Online Access:https://www.mdpi.com/1718-7729/32/1/6
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1718-7729/32/1/6

Similar Items